Kesimpta (ofatumumab) is a prescription medication used in the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is a monoclonal antibody that targets CD20, a protein found on the surface of B cells, which are a type of white blood cell involved in the immune response. By binding to CD20, Kesimpta helps deplete these B cells, which are believed to play a key role in the nerve damage associated with MS. This medication is administered through subcutaneous injections, offering a convenient dosing schedule that starts with an initial dosing period followed by monthly injections. Kesimpta has been shown to reduce the rate of relapses, slow the progression of disability, and impact the number of new or enlarging brain lesions in people with MS, making it an important option in the management of this chronic condition.